Outset Medical, Inc. (OM)
Outset Medical, Inc. (OM)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,978 | -19,491 | -17,838 | -44,324 |
| Loss on disposal of property and equipment | NaN | 0 | -3 | -2 |
| Stock-based compensation expense | 3,453 | 4,063 | 5,080 | 6,473 |
| Depreciation and amortization | 795 | 881 | 1,011 | 2,449 |
| Non-cash lease expense | 387 | 410 | 401 | 772 |
| Non-cash interest expense | 700 | 713 | 710 | 1,335 |
| Amortization of premium on investments, net | 413 | 536 | 689 | 1,028 |
| Change in provision for inventories | 95 | 79 | -43 | -160 |
| Change in provision for credit losses | -402 | 2,865 | -972 | 1,622 |
| Loss on extinguishment of term loan | 0 | 0 | 0 | -7,685 |
| Accounts receivable | -3,409 | -1,768 | -2,900 | 893 |
| Inventories | 2,244 | -1,492 | -3,004 | -7,297 |
| Prepaid expenses and other assets | -932 | 1,300 | 108 | -468 |
| Accounts payable | 865 | -1,129 | 338 | -2,502 |
| Accrued compensation and related benefits | -1,980 | -120 | 1,066 | -7,032 |
| Accrued expenses and other current liabilities | 2,166 | 2,735 | -1,826 | 610 |
| Accrued warranty liability | -22 | 11 | 123 | -698 |
| Deferred revenue | -1,194 | -1,375 | 980 | 999 |
| Operating lease liabilities | -413 | -587 | -460 | -866 |
| Accrued interest | 0 | 0 | 0 | -2,695 |
| Net cash used in operating activities | -12,844 | -9,521 | -6,320 | -30,486 |
| Purchases of property and equipment | 65 | 223 | 160 | 415 |
| Purchases of investment securities | 22,895 | 28,221 | 40,095 | 153,653 |
| Sales and maturities of investment securities | 30,859 | 37,034 | 43,222 | 44,827 |
| Net cash provided by (used in) investing activities | 7,899 | 8,590 | 2,967 | -109,241 |
| Proceeds from espp purchases | 506 | 0 | 231 | 408 |
| Payments on finance lease liabilities | 5 | NaN | NaN | NaN |
| Repayment of term loan and extinguishment costs | 0 | 0 | 0 | 204,954 |
| Proceeds from issuance of term loan, net of issuance costs | 0 | 0 | 0 | 98,270 |
| Proceeds from issuance of series a convertible preferred stock, net of issuance costs | 0 | 0 | 0 | 161,548 |
| Payment of deferred financing costs | NaN | 0 | NaN | NaN |
| Net cash provided by financing activities | 501 | 0 | 231 | 55,272 |
| Net decrease in cash, cash equivalents and restricted cash | -4,444 | -931 | -3,122 | -84,455 |
| Cash, cash equivalents and restricted cash as of beginning of period | 38,835 | 39,766 | 127,343 | NaN |
| Cash, cash equivalents and restricted cash as of end of period | 34,391 | 38,835 | 39,766 | NaN |